Palmatine inhibits growth and invasion in prostate cancer cell: Potential role for rpS6/NFκB/FLIP. Issue 10 (7th July 2014)

• Record Type: Journal Article
• Authors: Hambright, Heather G.; Batth, Izhar Singh; Xie, Jianping; Ghosh, Rita; Kumar, Addanki Pratap
• Is Part Of: Molecular carcinogenesis. Volume 54:Issue 10(2015:Oct.)
• Page Start: 1227
• Page End: 1234
• Publication Date: 2014-07-07
• Subjects: palmatine -- prostate cancer -- rpS6; Carcinogenesis -- Molecular aspects -- Periodicals; 616.994071
• DOI: 10.1002/mc.22192
• Languages: English
• ISSNs: 0899-1987

Abstract

Abstract : Novel agents are desperately needed for improving the quality of life and 5‐year survival to more than 30% for metastatic castrate‐resistant prostate cancer. Previously we showed that Nexrutine, Phellodendron amurense bark extract, inhibits prostate tumor growth in vitro and in vivo. Subsequently using biochemical fractionation we identified butanol fraction contributes to the observed biological activities. We report here that palmatine, which is present in the butanol fraction, selectively inhibits growth of prostate cancer cells without significant effect on non‐tumorigenic prostate epithelial cells. By screening receptor tyrosine kinases in a protein kinase array, we identified ribosomal protein S6, a downstream target of p70S6K and the Akt/mTOR signaling cascade as a potential target. We further show that palmatine treatment is associated with decreased activation of NFκB and its downstream target gene FLIP. These events led to inhibition of invasion. Similar results were obtained using parent extract Nexrutine (Nx) suggesting that palmatine either in the purified form or as one of the components in Nx is a potent cytotoxic agent with tumor invasion inhibitory properties. Synergistic inhibition of rpS6/NFκB/FLIP axis with palmatine may have therapeutic potential for the treatment of prostate cancer and possibly other malignancies with their constitutive activation. These data support a biological link between rpS6/NFκB/FLIP in mediating palmatine‐induced inhibitory effects and warrants additional preclinical studies to test its therapeutic efficacy. © 2014 Wiley Periodicals, Inc.